Oncofetal protein IMP3: A novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas

Cancer

Volumn 112, Issue 12, 2008, Pages 2676-2682

  Jiang, Zhong ^a,e   Lohse, Christine M ^b   Chu, Peigou G ^c   Wu, Chin Lee ^d   Woda, Bruce A ^a   Rock, Kenneth L ^a   Kwon, Eugene D ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Three Biotech ^*  (United States)

Author keywords

Chromophobe renal cell carcinoma; IMP3; mRNA binding protein; Oncofetal protein; Papillary renal cell carcinoma; Prognostic biomarker

Indexed keywords

ONCOFETAL ANTIGEN; PROTEIN IMP3; RNA BINDING PROTEIN; IMP 3 PROTEIN, HUMAN; IMP-3 PROTEIN, HUMAN; ONCOFETAL ANTIGENS; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EVALUATION; KIDNEY TUMOR; MULTICENTER STUDY; PATHOLOGY;

ANTIGENS, NEOPLASM; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM PROTEINS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 46049114743     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23484     Document Type: Article

References (34)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma [review]. N Engl J Med. 2005;353:2477-2490.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma [see comment] [review]. N Engl J Med. 1996;335:865-875.
3. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States [see comment]. JAMA. 1999;281:1628-1631.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
5. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:987-989.
6. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours [review]. J Pathol. 1997;183:131-133.
7. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases [see comment]. Am J Surg Pathol. 2002;26:281-291.
8. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases [see comment]. Am J Surg Pathol. 1997;21:621-635.
9. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-624.
10. Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology. 2002;59:532-537.
11. Ljungberg B, Alamdari FI, Stenling R, Roos G. Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol. 1999;36:565-569.
12. Lohse CM, Cheville JC. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma [review]. Clin Lab Med. 2005;25:433-464.
13. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89:604-614.
14. Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004;11:71-77.
15. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262-1270.
16. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88:95-99.
17. Monk D, Bentley L, Beechey C, et al. Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome. J Med Genet. 2002;39:575-581.
18. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14:2729-2733.
19. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer. 2003;88:887-894.
20. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188-195.
21. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005;280:18517-18524.
22. Vikesaa J, Hansen TV, Jonson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 2006;25:1456-1468.
23. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556-564.
24. Hoffmann NE, Sheinin Y, Lohse CM, et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008;112:1471-1479.
25. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma [review]. J Urol. 2000;163:408-417.
26. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma [see comment]. N Engl J Med. 2007;356:125-134.
27. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma [review]. J Clin Oncol. 2006;24:5601-5608.
28. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [see comment]. N Engl J Med. 2007;356:115-124.
29. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma [see comment]. JAMA. 2006;295:2516-2524.
30. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
31. Yaniv K, Fainsod A, Kalcheim C, Yisraeli JK. The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development. 2003;130:5649-5661.
32. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537-544.
33. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590-595.
34. Gunawan B, von Heydebreck A, Fritsch T, et al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res. 2003;63:6200-6205.